The Cell and Gene Therapy Catapult, one of UK’s centers of excellence, has partnered with Japan’s Forum for Innovative Regenerative Medicine to boost their respective stances in the global cell and gene therapy landscape.
The Cell and Gene Therapy Catapult (CGT Catapult), a UK center of excellence for building up the cell and gene therapy sector in the UK, announced on Oct. 3, 2017 that it has signed a Memorandum of Understanding (MoU) with Japan’s Forum for Innovative Regenerative Medicine (FIRM) to explore the possibility of a cooperative relationship that will raise the international reach of the respective organizations.
Through this collaboration, FIRM and the CGT Catapult will share information regarding regenerative medicine technologies, policies, and legal issues by connecting major industry players in Japan and the UK. The organizations aim to increase the profile and standing of their countries in the global cell and gene therapy space through combined efforts that are outlined within the MoU.
FIRM, an incorporated association focused on accelerating research and commercialization of regenerative medicine, works closely with the Japanese government and academia to establish a social structure to safely and continuously deliver regenerative medicinal products. FIRM comprises more than 230 Japanese, including organizations from various fields such as pharmaceuticals, biotechnology, manufacturing, transportation, and insurance. These organizations offer their respective experience to the research, development, and delivery of regenerative medicine. FIRM promotes the applied use of technological developments through policy, commercialization, and network support.
Source: Cell and Gene Therapy Catapult
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.